Surgical rates in subprovincial areas across Canada: rankings of 39 procedures in order of variation
…, E Vayda, GF Parsons, MN Walsh - Canadian Journal of …, 1996 - ncbi.nlm.nih.gov
… Valvotomy or valvuloplasty with or without replacement of heart valve (47.0–47.2)6 N …
Table I also identifies the 15 procedures classified as primarily discretionary (denoted by D) …
Table I also identifies the 15 procedures classified as primarily discretionary (denoted by D) …
Hysterectomy rates by diagnosis: variation among Canadian census divisions
E Vayda, JF Gentleman, MN Walsh, GF Parsons - Journal SOGC, 1996 - Elsevier
Les taux d’hystérectomies comptent au nombre des taux d’interventions chirurgicales les
plus variables au Canada. Dans le présent article, nous examinons les taux d’hystérectomies …
plus variables au Canada. Dans le présent article, nous examinons les taux d’hystérectomies …
[HTML][HTML] Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double …
Background A safe, effective, and rapidly scalable vaccine against Zika virus infection is
needed. We developed a purified formalin-inactivated Zika virus vaccine (ZPIV) candidate that …
needed. We developed a purified formalin-inactivated Zika virus vaccine (ZPIV) candidate that …
Assessment of extracellular dehydration using saliva osmolality
Introduction When substantial solute losses accompany body water an isotonic hypovolemia
(extracellular dehydration) results. The potential for using blood or urine to assess …
(extracellular dehydration) results. The potential for using blood or urine to assess …
[HTML][HTML] Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a …
…, MC Keefer, Y Meng, NL Michael… - The Lancet Infectious …, 2022 - thelancet.com
Background We evaluated our SARS-CoV-2 prefusion spike recombinant protein vaccine (CoV2
preS dTM) with different adjuvants, unadjuvanted, and in a one-injection and two-…
preS dTM) with different adjuvants, unadjuvanted, and in a one-injection and two-…
[HTML][HTML] Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized …
…, J Treanor, N Turet, R Froget, S Walsh… - …, 2023 - thelancet.com
Background In a parallel-group, international, phase 3 study (ClinicalTrials.gov NCT04762680),
we evaluated prototype (D614) and Beta (B.1.351) variant recombinant spike protein …
we evaluated prototype (D614) and Beta (B.1.351) variant recombinant spike protein …
[HTML][HTML] Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind …
Background The development of an effective vaccine against Zika virus remains a public
health priority. A Zika purified inactivated virus (ZPIV) vaccine candidate has been shown to …
health priority. A Zika purified inactivated virus (ZPIV) vaccine candidate has been shown to …
Clinical and demographic factors associated with COVID-19, severe COVID-19, and SARS-CoV-2 infection in adults: a secondary cross-protocol analysis of 4 …
…, HG Gelderblom, R McClennen, N Michael… - JAMA network …, 2023 - jamanetwork.com
Importance Current data identifying COVID-19 risk factors lack standardized outcomes and
insufficiently control for confounders. Objective To identify risk factors associated with COVID-…
insufficiently control for confounders. Objective To identify risk factors associated with COVID-…
Efficacy of a bivalent (D614+ B. 1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind …
GH Dayan, N Rouphael, SR Walsh, A Chen… - The Lancet …, 2023 - thelancet.com
Background COVID-19 vaccines with alternative strain compositions are needed to provide
broad protection against newly emergent SARS-CoV-2 variants of concern. This study aimed …
broad protection against newly emergent SARS-CoV-2 variants of concern. This study aimed …
[HTML][HTML] Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
…, N Rouphael, SR Walsh, A Chen, N Grunenberg… - …, 2023 - thelancet.com
Background The literature on first generation COVID-19 vaccines show they were less effective
against new SARS-CoV-2 variants of concern including Omicron (BA.1, BA.2, BA.4 and …
against new SARS-CoV-2 variants of concern including Omicron (BA.1, BA.2, BA.4 and …
